Can a booster shot for immune cells improve lymphoma treatment?

NCT ID NCT05075603

Completed Disease control Sponsor: NeoImmuneTech Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 07, 2026 · Updated 24 times

Summary

This early-phase study tested a drug called NT-I7 (a long-acting immune booster) given after standard CAR-T cell therapy in 17 adults with large B-cell lymphoma that had come back or not responded to prior treatments. The main goal was to check safety and find the best dose. Researchers also looked for signs that the drug might help the CAR-T cells work better against the cancer.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RECURRENT DIFFUSE LARGE B-CELL LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Barbara Ann Karmanos Cancer Hospital dba Karmanos Cancer Center

Detroit, Michigan, 48201, United States
City of Hope

Duarte, California, 91010, United States
Duke Cancer Institute

Durham, North Carolina, 27710, United States
Washington University in St. Louis

St Louis, Missouri, 63110, United States

Conditions

Explore the condition pages connected to this study.

RECURRENT DIFFUSE LARGE B-CELL LYMPHOMA REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED REFRACTORY HIGH GRADE B-CELL LYMPHOMA REFRACTORY TRANSFORMED FOLLICULAR LYMPHOMA TO DIFFUSE LARGE B-CELL LYMPHOMA